LY3556050

DRUG6 trials

Sponsors

Eli Lilly and Company

Conditions

Chronic Low-back PainDiabetic Peripheral Neuropathic PainHealthyOsteoarthritis

Phase 1

A Study of LY3556050 in Healthy Participants

CompletedNCT04156750

Eli Lilly and CompanyHealthy

Start: 2019-11-20End: 2020-08-03Updated: 2020-08-19

A Study of Single and Repeated Doses of LY3556050 in Healthy Participants

CompletedNCT05341102

Eli Lilly and CompanyHealthy

Start: 2016-09-14End: 2017-06-02Updated: 2022-04-22

A Study of Effect of LY3556050 on Metformin in Healthy Participants

CompletedNCT05615467

Eli Lilly and CompanyHealthy

Start: 2022-11-15End: 2022-12-27Updated: 2023-01-18

Phase 2

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis

CompletedNCT04627038

Eli Lilly and CompanyOsteoarthritis

Start: 2020-11-12End: 2021-10-21Updated: 2023-11-02

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain

TerminatedNCT04707157

Eli Lilly and CompanyDiabetic Peripheral Neuropathic Pain

Start: 2021-05-06End: 2022-06-13Updated: 2023-11-02

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain

CompletedNCT04874636

Eli Lilly and CompanyChronic Low-back Pain

Start: 2021-05-20End: 2022-02-09Updated: 2023-11-02